Pietrasz, Daniel http://orcid.org/0000-0002-0643-9917
Wang-Renault, Shufang
Taieb, Julien http://orcid.org/0000-0002-9955-4753
Dahan, Laetitia
Postel, Mathilde
Durand-Labrunie, Jerome
Le Malicot, Karine
Mulot, Claire
Rinaldi, Yves
Phelip, Jean-Marc
Doat, Solene
Blons, Hélène
de Reynies, Aurelien
Bachet, Jean-Baptiste
Taly, Valérie http://orcid.org/0000-0002-3116-8602
Laurent-Puig, Pierre http://orcid.org/0000-0001-8475-5459
Article History
Received: 24 June 2021
Revised: 20 October 2021
Accepted: 29 October 2021
First Online: 22 November 2021
Competing interests
: JT has received honoraria for speaker or advisory roles from AMGEN, Roche, MERCKKGaA, MSD, Lilly, Servier, Sanofi, Pierre Fabre, AstraZeneca, Samsung Bioepis, HallioDx. JBB has received personal fees from Amgen, AstraZeneca, Bayer, Merck Serono, Pierre Fabre, Roche, Sanofi, Servier, Shire, and non-financial support from Amgen, Merck Serono, and Roche. PLP declares consulting for or personal fees from Amgen, AstraZeneca, Biocartis, BMS, Boehringer-Ingelheim, Lilly, Merck Serono, MSD, Sanofi, Servier, Roche.
: All the patients included in the PLAPAN cohort signed an informed consent form approved by the ethics committee (CPP Ile-de-France 2014/59NICB). PRODIGE 35 PANOPTIMOX trial (NCT02352337) PRODIGE 37 FIRGEMAX (NCT 02827201) trials were approved by the ethics committee.